What is HC Wainwright's Forecast for RenovoRx Q3 Earnings?

Key Points

• HC Wainwright expects RenovoRx to report a Q3 2027 loss of $0.01 per share, compared with a full-year consensus loss estimate of $0.31 per share.
• RenovoRx’s latest quarterly results exceeded expectations, with an EPS loss of $0.05 versus the $0.07 estimate and revenue of $0.91 million versus the $0.70 million consensus.
• Analyst sentiment remains generally positive: the stock carries a “Moderate Buy” consensus rating and an average price target of $8.50, despite continued substantial losses and negative profitability metrics.

RenovoRx, Inc. (NASDAQ:RNXT - Free Report) - Analysts at HC Wainwright issued their Q3 2027 earnings estimates for shares of RenovoRx in a report released on Friday, August 14th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of ($0.01) for the quarter. The consensus estimate for RenovoRx's current full-year earnings is ($0.31) per share.

RenovoRx (NASDAQ:RNXT - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. The business had revenue of $0.91 million during the quarter, compared to the consensus estimate of $0.70 million. RenovoRx had a negative return on equity of 138.07% and a negative net margin of 621.71%.

Several other brokerages have also commented on RNXT. Ascendiant Capital Markets upped their price target on RenovoRx from $13.50 to $14.00 and gave the stock a "buy" rating in a research note on Monday, June 1st. Wall Street Zen raised RenovoRx from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, Weiss Ratings upgraded RenovoRx from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, RenovoRx presently has a consensus rating of "Moderate Buy" and an average target price of $8.50.

RenovoRx Stock Performance

Shares of RenovoRx stock opened at $1.40 on Monday. RenovoRx has a twelve month low of $0.70 and a twelve month high of $1.45. The stock has a market capitalization of $63.07 million, a P/E ratio of -4.52 and a beta of 0.99. The business's fifty day moving average price is $0.95 and its 200 day moving average price is $0.94.

Institutional Investors Weigh In On RenovoRx

Large investors have recently modified their holdings of the stock. XTX Topco Ltd raised its holdings in shares of RenovoRx by 58.6% during the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company's stock valued at $42,000 after buying an additional 18,525 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new position in RenovoRx in the 2nd quarter worth approximately $98,000. Citadel Advisors LLC purchased a new position in RenovoRx in the 3rd quarter worth approximately $154,000. Wealthspire Advisors LLC purchased a new position in RenovoRx in the 4th quarter worth approximately $212,000. Finally, Geode Capital Management LLC grew its position in RenovoRx by 9.9% in the second quarter. Geode Capital Management LLC now owns 353,603 shares of the company's stock valued at $467,000 after acquiring an additional 31,730 shares in the last quarter. Institutional investors and hedge funds own 3.10% of the company's stock.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company's lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source